The following articles are being highlighted as part of Circulation's Topic Review series. This series will summarize the most important manuscripts, as selected by the editors, published in Circulation and the Circulation subspecialty journals. The studies included in this article represent the most read manuscripts published on the topic of cardiovascular quality and outcomes within the last year.
Summary-The outcome of atrial fibrillation patients on warfarin partially depends on maintaining adequate time in therapeutic International Normalized Ratio (INR) range (TTR). Large differences in TTR have been reported between centers and countries, but the reasons are unclear. In the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, a warfarin dosing algorithm provided to participating centers recommended no change for in-range and 10% to 15% weekly dose changes for out-of-range INR values. We determined whether algorithm-consistent warfarin dosing could predict patient TTR and the composite outcome of stroke, systemic embolism, or major hemorrhage. Among 6022 nonvalvular atrial fibrillation patients from 44 countries, we found a strong association between the proportion of algorithm-consistent warfarin doses and mean country TTR (R 2 =0.65). The degree of algorithm-consistent warfarin dosing accounted for a majority of the TTR variation between centers and countries. Each 10% increase in center algorithm-consistent dosing independently predicted a 6.12% increase in TTR (95% confidence interval, 5.65-6.59), and an 8% decrease in rate of the composite clinical outcome (hazard ratio, 0.92; 95% confidence interval, 0.85-1.00). In summary, warfarin dosing practice that does not change the dose when the INR is in range, and that makes relatively small (10% to 15%) weekly dose adjustments when the INR is out of range, is associated with improved TTR and clinical outcomes. Systems that implement algorithm-based dosing for patients with atrial fibrillation on warfarin could potentially improve outcomes on a global scale, especially in centers and countries with suboptimal INR control.
Conclusions-Adherence, intentional or not, to a simple warfarin dosing algorithm predicts improved TTR and accounts for considerable TTR variation between centers and countries. Systems facilitating algorithm-based warfarin dosing could optimize anticoagulation quality and improve clinical outcomes in atrial fibrillation on a global scale. 1 
Outcomes of Medicare Beneficiaries Undergoing Catheter Ablation for Atrial Fibrillation
Summary-Catheter ablation is increasingly used in older patients with atrial fibrillation for whom medical therapy has failed. However, clinical trials of catheter ablation have enrolled relatively young patients with limited comorbidity. To describe the use of catheter ablation and associated outcomes in older persons with atrial fibrillation, we conducted a retrospective cohort study of 15 423 Medicare beneficiaries who underwent catheter ablation for atrial fibrillation between July 2007 and December 2009. For every 1000 procedures, there were 17 cases of hemopericardium requiring intervention, 8 cases of stroke, and 8 deaths within 30 days. More than 40% of patients required hospitalization within 1 year; however, atrial fibrillation or atrial flutter was the primary discharge diagnosis in only 38.4% of cases. Eleven percent of patients underwent repeat ablation within 1 year. Renal impairment, age ≥80 years, and heart failure were major risk factors for mortality within 1 year after catheter ablation. Whereas major complications after catheter ablation were associated with advanced age, they were fairly infrequent, and few patients underwent repeat ablation. Randomized trials are needed to assess the efficacy of catheter ablation in older adults and to better inform risk-benefit calculations for older patients with drug-refractory, symptomatic atrial fibrillation.
Conclusions-Major complications after catheter ablation for atrial fibrillation were associated with advanced age but were fairly infrequent. Few patients underwent repeat ablation. Randomized trials are needed to inform risk-benefit calculations for older persons with drug-refractory, symptomatic atrial fibrillation. Summary-Coronary stenting has become a standard of care for the treatment of medically refractory coronary artery disease, with approximately one third of percutaneous coronary interventions (PCIs) performed in women in the United States. Although procedural success rates are similar by sex, it remains unclear whether disparate in-hospital and long-term outcomes exist between the sexes. In addition, the long-term safety and effectiveness of drug-eluting stents relative to bare metal stents in women are poorly understood. Women have been underrepresented in prior clinical trials evaluating intracoronary stent technologies, and smaller historical observational studies have produced conflicting results. Data from >400 000 older individuals (≥65 years of age) from the National Cardiovascular Data Registry CathPCI Registry were linked to Medicare inpatient claims to study sex-specific in-hospital and long-term outcomes after an index stent procedure. Additionally, the long-term safety and effectiveness of drug-eluting stents versus bare metal stents were compared in women and men. In the contemporary PCI era, our study shows that elderly women undergoing index PCI remain at higher risk of in-hospital mortality and other complications compared with men. In contrast, long-term outcomes are similar or better in women than in men. The use of drug-eluting stents is associated with a similar benefit in both men and women. Further studies are needed to understand the causative factors for these findings.
Conclusions-In contemporary coronary stenting, women have a slightly higher procedural risk than men but have better long-term survival. In both sexes, use of a drug-eluting stent is associated with lower long-term likelihood for death, myocardial infarction, and revascularization. Summary-Although uncontrolled epidemiological analyses suggest that sex independently contributes to cardiovascular risk, there are limited controlled large-scale clinical studies on sex-specific cardiovascular outcome. Moreover, clinical trials are often hampered by the enrollment of few female patients. In our analyses based on the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET) and the parallel Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) with patients ≥55 years of age, we included a large proportion of female patients (29.7%). In these large interventional trials, we observed that sex greatly affects the occurrence of cardiovascular events in patients with vascular disease or high-risk diabetes mellitus. This ≈20% lower risk for combined cardiovascular events in female patients, who were under optimal, guideline-recommended pharmacological treatment, is driven mainly by a significantly lower incidence of acute myocardial infarction. However, it should be pointed out that diabetic female patients were characterized by a higher risk for acute myocardial infarction compared with diabetic male patients, whereas alcohol consumption resulted in significantly lower risk in women. Sex-and age-dependent analyses demonstrate that female patients develop cardiovascular end points ≈5 to 10 years later despite appropriately individualized cardioprotective therapy in both female and male patients. In these controlled cardiovascular end-point trials, we clearly point out significant sex-related differences, with women being at lower net cardiovascular risk than men except when diabetic. These differences should be acknowledged in daily clinical routine when female and male patients at high cardiovascular risk are treated.
Conclusions-In our analysis made up of 70.3% male and 29.7% female patients, an ≈20% lower risk for the combined cardiovascular end points in female patients was observed despite treatment with cardioprotective agents. This difference was driven primarily by a significantly lower incidence of myocardial infarction. Thus, we demonstrate in a large interventional trial that sex greatly affects the occurrence of cardiovascular events in patients with vascular disease or high-risk diabetes mellitus. 
Influenza Vaccination and Major Adverse Vascular Events in High-Risk Patients
Summary-It remains uncertain whether the influenza vaccine is associated with a reduced risk of vascular events, despite at least 10 observational studies and 3 small randomized controlled trials investigating this association. The existing observational studies were limited by small size, involved only a single influenza season, and/ or were at risk of significant bias resulting from study design and the presence of confounding. The 3 randomized controlled trials were small with few event rates, precluding any definitive conclusions. We therefore performed an observational study using data from a large multinational trial of patients at high risk for vascular events involving 31 546 participants from 733 centers in 40 countries. Although initial analyses suggest that influenza vaccination was associated with a reduced risk of major adverse vascular events during influenza seasons when the influenza vaccine matched the circulating virus, detailed sensitivity analyses revealed that evidence of risk of confounding bias remained. A randomized trial is needed to definitively address this question.
Conclusions-Although initial analyses suggest that influenza vaccination was associated with reduced risk of major adverse vascular events during influenza seasons when the influenza vaccine matched the circulating virus, sensitivity analyses revealed that risk of bias remained. A randomized trial is needed to definitively address this question.
Expansion of a Regional ST-Segment-Elevation Myocardial Infarction System to an Entire State
Summary-Many of the decisions and processes that affect the speed of coronary artery reperfusion occur long before patients reach the cardiologist. Particularly in the case of patients who are diagnosed with ST-segment-elevation myocardial infarction (STEMI) on scene by paramedics, early catheterization laboratory activation can lead to reperfusion times <1 hour. Similarly, patients presenting to hospitals without primary percutaneous coronary intervention capability require coordinated protocols for diagnosis and transfer to be treated in <2 hours. In both scenarios, accelerated coronary reperfusion has been associated with improved survival. This article describes the largest voluntary statewide system for ST-segment-elevation myocardial infarction diagnosis and treatment. The North Carolina Regional Approach to Cardiovascular Emergencies (RACE) system included every percutaneous coronary intervention hospital (n=21), most hospitals lacking percutaneous coronary intervention capability (n=98), and >500 emergency medical service agencies in a state of 9 million people. Over a 2-year period, the implementation of common protocols resulted in significantly improved treatment times for patients presenting directly to percutaneous coronary intervention hospitals and patients requiring hospital transfer. Similar to prior work, treatment within guideline goals was associated with significantly lower mortality compared with those exceeding guideline goals (2.2% versus 5.7%; P<0.001).
Conclusions-Through extension of regional coordination to an entire state, rapid diagnosis and treatment of ST-segment-elevation myocardial infarction has become an established standard of care independently of healthcare setting or geographic location. . Using multivariable models, we examined trends in therapies and outcomes. There were 55% of patients with HF-reduced EF, 14% with HF-borderline EF, and 36% with HF-preserved EF. From 2005 to 2010, the proportion of hospitalizations for HF-preserved EF increased from 33% to 39% (P<0.0001). Although many heart failure quality metrics cannot be applied appropriately to the HF-preserved EF population, there are broadly applicable cardiovascular prevention goals such as blood pressure control and discharge instructions that are particularly important for patients with HF-preserved EF but less likely to be achieved. In-hospital mortality for patients with HF-preserved EF remains comparable to that for patients with HF-reduced EF. Inhospital mortality for HF-preserved EF decreased from 3.32% in 2005 to 2.35% in 2010 but was stable for patients with HF-reduced EF. Among hospitalizations for heart failure, HF-preserved EF represents a growing proportion and may overtake HF-reduced EF as the predominant form of acute heart failure. There remains an important opportunity for identification of evidence-based therapies in patients with HF-preserved EF.
Conclusions-Hospitalization for HF-preserved EF is increasing relative to HF-reduced EF. Although in-hospital mortality for patients with HF-preserved EF declined over the study period, an important opportunity remains for identifying evidence-based therapies in patients with HF-preserved EF. Summary-In an acute cardiac event, access to timely and definitive care through specialist centers is critical to survival and to improving longer-term outcomes. Similarly, for survivors, ready access to more routine health care, including specialist management (through a cardiologist and cardiac rehabilitation program) and communitybased primary care, is essential in preventing potentially fatal secondary events. Although evidence-based guidelines provide advice on managing a cardiac event in ideal circumstance, in reality, their implementation is often limited by the geographic location of the initial acute event and the location and level of facilities available to manage that event in a timely manner. For example, only an estimated 20% of emergency departments in the United States are located in hospitals with a cardiac catheterization laboratory. Still fewer have the capability to perform immediate revascularization. These data reinforce the importance of ready access to more portable and potentially life-saving therapies such as defibrillators and thrombolytic therapy, as well as efficient cardiac triage and transportation. The Cardiac Accessibility and Remoteness Index of Australia (Cardiac ARIA) measured access to cardiac care through a geographic lens via an objective, comparable measure of the time and distance from any population location to evidence-based cardiac care. An index of access to health services that was independent of professional, socioeconomic, or political influences was generated. It highlighted substantial inequities in access to cardiac services in Australia. Cardiac ARIA represents a powerful and adaptable tool to optimize outcomes by informing more equitable distribution of cost-effective, life-saving health care in any given geographic location.
Conclusions-The
Cardiac ARIA index demonstrated substantial inequity in access to cardiac services in Australia. This methodology can be used to inform cardiology health service planning and could be applied to other common disease states within other regions of the world. relationship between country-level economic and health system factors and the risk of elevated cholesterol (total cholesterol levels >200 mg/dL). The analysis was performed separately for patients with versus without previous history of hyperlipidemia; a higher proportion of the total variability in elevated cholesterol was at the country level for patients with (12.1%) versus without (7.4%) history of hyperlipidemia. Among patients with history of hyperlipidemia, after adjusting for patient-level demographic and clinical characteristics and average fat consumption at the country level, countries in the highest tertile of gross national income or World Health Organization index of health system achievement were found to have significantly lower odds of elevated cholesterol than those in each of the lower 2 tertiles, and the odds of elevated cholesterol was higher for countries in higher versus lower tertile of out-of-pocket health expenditures. No significant associations between country-level factors and elevated cholesterol were found for patients without history of hyperlipidemia. These results support the need for strengthening efforts toward effective cardiovascular disease prevention and control and may provide insight for health policy setting at the national level.
Conclusions-Global variations in the prevalence of elevated cholesterol among patients with history of hyperlipidemia are associated with country-level economic development and health system indices. These results support the need for strengthening efforts toward effective cardiovascular disease prevention and control and may provide insight for health policy setting at the national level. Early mortality is predicted by variables related to acuteness of presentation, whereas longer-term mortality is associated with chronic debilitating diseases such as insulin-dependent diabetes mellitus and dialysis-dependent renal failure and behaviors such as cigarette smoking. The model may be used for shared medical decision making, quality improvement, and provider benchmarking and as a basis for developing comparative effectiveness research.
Conclusions-On the basis of the large and nationally representative CathPCI Registry, we have developed a model that has excellent discrimination, calibration, and validation to predict survival up to 3 years after percutaneous coronary intervention. Conclusions-Using clinical registry data and longitudinal claims data, we developed a long-term survival prediction model for isolated coronary artery bypass grafting. This provides valuable information for shared decision making, comparative effectiveness research, quality improvement, and provider profiling.
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Admission International Normalized Ratio Levels, Early Treatment Strategies, and Major Bleeding Risk Among Non-ST-SegmentElevation Myocardial Infarction Patients on Home Warfarin Therapy: Insights From the National Cardiovascular Data Registry
Summary-Little is known about the contemporary treatment patterns and bleeding risks of non-ST-segment-elevation myocardial infarction patients on home warfarin therapy. Although expert opinion from consensus guidelines suggests withholding parenteral anticoagulant therapy in patients with admission international normalized ratio (INR) levels ≥2.0, we found that 45% of these patients were prescribed early heparin in the first 24 hours of hospitalization. Additionally, although guidelines suggest initiation of antiplatelet therapy among those with admission INR levels ≥2.0, we found that only 35% and 14% of these patients were prescribed early clopidogrel and glycoprotein IIb/IIIa inhibitor, respectively. Patients with admission INR ≥2.0 were less likely to receive an early invasive strategy despite higher ischemic risk. These findings highlight the challenge that clinicians face in balancing ischemic benefit and bleeding risk when selecting a treatment for these patients. We found that early use of antiplatelet and antithrombin therapy was associated with increased bleeding risk among non-ST-segmentelevation myocardial infarction patients on home warfarin; however, an early invasive strategy was not. After adjustment, patients with admission INR levels >3.0 were at highest risk of in-hospital major bleeding followed by those with admission INR of 2.0 to 3.0. Early
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antithrombotic treatment was associated with increased bleeding risk regardless of admission INR level. Future clinical trials are critically needed to guide treatment decisions, to determine the optimal use and timing of anticoagulant therapy, and to formulate more definitive guideline recommendations that balance the prevention of adverse ischemic events with the risk of major bleeding in this vulnerable population.
Conclusions-National patterns of early antithrombotic treatment for non-ST-segment-elevation myocardial infarction patients on home warfarin diverge from expert opinion provided by current practice guidelines. Early antithrombotic treatment was associated with increased bleeding risk regardless of admission INR level. We projected that over a patient's lifetime, TAVR would increase life expectancy by 1.9 years (1.6 years after application of a standard 3% discount rate to future costs and benefits) at a discounted lifetime incremental cost of $79 837. The incremental cost-effectiveness ratio for TAVR was thus estimated at $50 200 per year of life gained, or $61 889 per quality-adjusted life-year gained, values generally considered acceptable within the context of the US healthcare system. These estimates were only slightly altered when assumptions about future costs and survival were varied within plausible ranges.
Conclusions-For patients with severe aortic stenosis who are not candidates for surgery, TAVR increases life expectancy at an incremental cost per life-year gained well within accepted values for commonly used cardiovascular technologies. Summary-Community-acquired pneumonia (CAP) is a common infection and a leading cause of morbidity and mortality that tends to occur in patients at high cardiovascular risk (ie, the elderly, smokers, diabetics, patients with chronic cardiac conditions). Community-acquired pneumonia can trigger acute cardiac complications. This study analyzed a prospective cohort of 2287 patients with community-acquired pneumonia in whom the 30-day incidence of cardiac complications was investigated. New or worsening heart failure, new or worsening arrhythmias, and myocardial infarction occurred in 20.8%, 11%, and 3% of inpatients and in 1.4%, 1%, and 0.1% of outpatients, respectively. Several patients had more than one of these conditions. Overall, cardiac complications (1 or more of the cardiac events above) were diagnosed in 27% and 2% of inpatients and outpatients, respectively. A majority of cardiac complications in both groups (89% inpatients and 75% outpatients) were diagnosed within the first week, more than half of them in the first 24 hours. Risk factors for cardiac complications included older age, nursing home residence, preexisting cardiovascular disease, and pneumonia severity. The occurrence of cardiac complications was associated with an adjusted 60% increase in risk of death at 30 days. Clinicians must recognize the burden of cardiac complications in patients with community-acquired pneumonia and exercise appropriate clinical alertness for their timely recognition. Rates of influenza and pneumococcal vaccination in groups of high cardiac risk need to be optimized. Further research to test risk stratification, prevention, and treatment strategies for incident cardiac complications in patients with community-acquired pneumonia may reduce the burden of death associated with this infection.
Conclusions-Incident cardiac complications are common in patients with community-acquired pneumonia and are associated with increased short-term mortality. Older age, nursing home residence, preexisting cardiovascular disease, and pneumonia severity are associated with their occurrence. Further studies are required to test risk stratification and prevention and treatment strategies for cardiac complications in this population. Summary-Acute kidney injury (AKI) is a risk factor for long-term adverse outcomes, including acute myocardial infarction and death. We sought to explore the relationship between severity of AKI and in-hospital outcomes in the setting of acute myocardial infarction using the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG), a nationwide sample of myocardial infarction patients admitted to 383 hospitals in the United States. AKI was defined using absolute changes in serum creatinine (SCr; peak SCr minus admission SCr) and categorized as no AKI (SCr change, <0.3 mg/dL), mild AKI (SCr change, 0.3-<0.5 mg/dL), moderate AKI (SCr change, 0.5-<1.0 mg/ dL), and severe AKI (SCr change, ≥1.0 mg/dL). Overall, in-hospital mortality rates for those with mild, moderate, and severe AKI were 6.6%, 14.2%, and 31.8% compared with 2.1% without AKI and demonstrated similar increases in subgroups with or without prior chronic kidney disease, in-hospital shock, or coronary artery bypass graft surgery. In multivariable regression, the adjusted odds ratios for in-hospital death were 2.4 (95% confidence interval, 2.0-2.7), 4.5 (95% confidence interval, 3.9-5.1), and 12.6 (95% confidence interval, 11.1-14.3) for mild, moderate, and severe AKI compared with those without AKI. Although patients with AKI were less likely to undergo early invasive care or to receive antiplatelet therapies, rates of major bleeding ranged from 8.4% (no AKI) to 32.7% (severe AKI). AKI is common, occurring in 16% of acute myocardial infarction patients. Furthermore, it is strongly associated with mortality and bleeding, underscoring the importance of efforts to identify risk factors and to prevent AKI in acute myocardial infarction care. June 11, 2013
Conclusions-AKI is common and associated with mortality and bleeding, underscoring the importance of efforts to identify risk factors and to prevent AKI in acute myocardial infarction care. Conclusions-When generic high-potency statins are available, noninvasive cardiac stress testing to target preventive medications is not cost effective unless it substantially improves adherence.
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Physician Procedure Volume and Complications of Cardioverter-Defibrillator Implantation
Summary-The outcomes of procedures are often better when they are performed by more experienced physicians and in hospitals with higher procedure volumes. This study examined the relationship between physician procedure volume and in-hospital complications and death after implantation of an implantable cardioverterdefibrillator using data from a national clinical registry of implantable cardioverter-defibrillator procedures. A significant inverse relationship between physician procedure volume and the rate of implantable cardioverter-defibrillator procedural complications was demonstrated, which was not explained by physician specialty, hospital volume, or patient characteristics. These data suggest that concentrating implantable cardioverter-defibrillator implantation in the hands of more experienced physicians may reduce procedural complications.
Conclusions-Physicians who implant more implantable cardioverter defibrillators (ICD) have lower rates of procedural complications and in-hospital mortality, independent of hospital procedure volume, physician specialty, and ICD type. has previously been shown to beneficially affect cardiovascular risk factors, eg, hypertension, psychological stress, substance abuse, insulin resistance, myocardial ischemia, left ventricular mass and carotid atherosclerosis. This randomized, controlled trial found that adding stress-reducing Transcendental Meditation to usual care in patients with coronary heart disease resulted in a 48% reduction in the risk for cardiovascular clinical events, that is, mortality, myocardial infarction, and stroke during >5 years of follow-up. Potential mechanisms for the observed differences in survival include lower blood pressure and anger scores. There was evidence for dose-response effect between regularity of meditation practice and longer survival. The Transcendental Meditation program may be useful in the secondary prevention of cardiovascular disease.
Conclusions-A selected mind-body intervention, the transcendental meditation program, significantly reduced risk for mortality, myocardial infarction, and stroke in coronary heart disease patients. These changes were associated with lower blood pressure and psychosocial stress factors. Therefore, this practice may be clinically useful in the secondary prevention of cardiovascular disease.
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Systematic Review and Adjusted Indirect Comparison Meta-Analysis of Oral Anticoagulants in Atrial Fibrillation
Summary-Direct comparative trials of newer oral anticoagulant agents are not available to help guide treatment choice. Adjusted indirect-comparison meta-analysis can be utilized to estimate efficacy and treatment differences when a common comparator is used. Most analyses identified no difference between agents. Apixaban was associated with a lower risk of major and gastrointestinal bleeding versus dabigatran and rivaroxaban, whereas dabigatran was associated with a lower risk of the composite of stroke or systemic emboli and ischemic stroke versus rivaroxaban. Meta-regression analyses identified no confounding of effect when controlled for differences in CHADS 2 score or time within the therapeutic international normalized ratio range.
Conclusions-Significant differences in efficacy and safety parameters may exist between oral anticoagulant agents in patients with atrial fibrillation. Apixaban lowers the risk of major and gastrointestinal bleeding versus dabigatran and rivaroxaban. Dabigatran lowers the composite of stroke or systemic emboli, and ischemic stroke versus rivaroxaban. Head-to-head clinical trials are required to confirm these findings.
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Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study
Summary-The use of chlorthalidone therapy for the treatment of hypertension has been questioned because of its associated increased risk of elevated glucose levels and diabetes compared with other blood pressure-lowering medications. In a prior report from ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), the increased risk of diabetes with chlorthalidone therapy versus angiotensin-converting enzyme inhibitor or calcium channel blocker therapy was modest and did not translate into more cardiovascular disease compared with diabetes during an average of 2.9 years of follow-up for postdevelopment of newonset diabetes during the first 2 years of ALLHAT. ALLHAT participant follow-up was extended up to an average of 6.9 years through querying national databases and confirms our prior findings. Although chlorthalidone therapy is associated with an increased risk of diabetes compared with other blood pressure-lowering medications, diabetes associated with chlorthalidone use has lower long-term cardiovascular disease risk than diabetes associated with angiotensin-converting enzyme inhibitor or calcium channel blocker use. The risk of diabetes associated with chlorthalidone should not deter clinicians from using it long-term.
Conclusions-The findings suggest that thiazide-related incident diabetes has less adverse long-term cardiovascular disease impact than incident diabetes that develops while on other antihypertensive medications.
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Addition of Frailty and Disability to Cardiac Surgery Risk Scores Identifies Elderly Patients at High Risk of Mortality or Major Morbidity
Summary-Prediction of operative risk using available risk scores is less accurate in elderly patients referred for cardiac surgery. Elderly patients often present with a heavy burden of comorbidity, disability, and perceived frailty. Multiple scales exist to measure surgical risk as well as frailty and disability, yet the optimal combination of scales remains unknown. Frailty and disability provide incremental prognostic value above surgical risk scores for predicting mortality or major morbidity. The optimal combination of scales consists of the Parsonnet surgical risk score, 5-meter gait speed as a measure of frailty, and the Nagi scale as a measure of disability.
Conclusions-Clinicians should use an integrative approach combining frailty, disability, and risk scores to better characterize elderly patients referred for cardiac surgery and identify those that are at increased risk.
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Incidence and Prevalence of Atrial Fibrillation and Associated Mortality Among Medicare Beneficiaries: 1993 to 2007
Summary-Atrial fibrillation (AF) is associated with considerable morbidity and mortality. The frequency of AF increases with age, but nationally representative data about incidence and prevalence in the United States are limited. AF leads to significant health care resource use and substantial economic burden, including annual Medicare expenditures of approximately $8 billion. From 1993 to 2007, the incidence of AF in the Medicare population remained steady, ranging from 27.3 to 28.3 per 1000 person-years. Incidence rates were consistently higher among men and white beneficiaries. The prevalence of AF increased throughout the study period at a mean rate of 5% per year. Mortality after AF diagnosis declined slightly but remained high; age-and sex-adjusted mortality in 2007 was 11% at 30 days and 25% at 1 year. Incident AF is common in the Medicare population and is associated with significant comorbidity and mortality; death occurs in one-quarter of beneficiaries within 1 year.
Conclusions-Among older Medicare beneficiaries, incident AF is common and has remained relatively stable for more than a decade. Incident AF is associated with significant comorbidity and mortality; death occurs in one-quarter of beneficiaries within 1 year. 23 
